A PNAS study strips LSD down to its minimal pharmacophore and finds safer, less hallucinogenic analogues.
Nine simplified ergolines were profiled across 5-HT2A/2B/2C; UCD0076 prefers 5-HT2C, shows antipsychotic-like effects in mice and avoids LSD's cardiotoxic liability. A separate report has a non-hallucinogenic LSD analogue boosting anti-tumour immunity in colorectal cancer models.